Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
55 hedge funds and large institutions have $258M invested in Unity Biotechnology in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 7 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
31% more funds holding
Funds holding: 42 → 55 (+13)
26% more capital invested
Capital invested by funds: $204M → $258M (+$53.2M)
0.73% more ownership
Funds ownership: 3.01% → 3.74% (+0.73%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.61M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$5.65M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.19M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTC
NF Trinity Capital
Central,
Hong Kong
|
-$9.9M |
| 2 |
AG
Artal Group
Luxembourg
|
-$815K |
| 3 |
Millennium Management
New York
|
-$666K |
| 4 |
Morgan Stanley
New York
|
-$634K |
| 5 |
D.E. Shaw & Co
New York
|
-$183K |
UBX Hedge Fund Activity: Q4 2018 in Review
55 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2018, worth a combined $258M — up 26% from $204M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new UBX positions and 7 closed out — a net gain of 13 holders — while 21 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $20M. The largest seller was NF Trinity Capital, exiting entirely with an estimated $9.9M sold.
- 55 institutional investors held Unity Biotechnology (UBX) as of Q4 2018, up from 42 in Q3 2018.
- Funds reported $258M of Unity Biotechnology stock for Q4 2018, up 26% quarter-over-quarter.
- 20 funds opened new Unity Biotechnology positions in Q4 2018 and 7 closed out, a net change of +13 holders.
- The largest Unity Biotechnology buyer in Q4 2018 was BlackRock, an estimated $20M added.
- The largest Unity Biotechnology seller in Q4 2018 was NF Trinity Capital, an estimated $9.9M sold.
Based on aggregated 13F filings for Q4 2018.